It does make you wonder why he's trying so hard to post so much misinformation/disinformation bullshit as if he's throwing shit at the wall in hopes something will stick at a trading forum that actually doesn't care considering we're now traversing the Pandemic into an Endemic. These types of posters must be from the same comedy group or stay up late at night to print misinformation posters so that they can go outside and staple them on their neighborhood utility poles. Actually, it's some kind'uv psychotic behavior but I'm trying very hard not to laugh at it because that would be disrespectful towards those that clearly need mental help. _______________________ .....Speaking to Der Spiegel magazine, Carsten Tschöpe, a cardiologist and head of the cardiomyopathy unit at Berlin’s Charité hospital, pointed out the potentially serious long-term consequences of a COVID infection. With the blood vessels, SARS-CoV-2 attacks “a very central structure of the body.” There is no organ in the human body that was not dependent on blood vessels, he said. “The organs lose parts of their function when they are no longer sufficiently supplied with blood. This causes global damage throughout the body.” According to the magazine, Tschöpe was convinced “that COVID late effects also contributed to the 19 percent excess mortality in October.” Other scientists also cite the earlier-than-usual onset of the flu epidemic and the circulation of other respiratory illnesses as possible contributors to the high excess mortality. The flu epidemic had been absent in recent years due to existing pandemic measures around the world. Once these were lifted, the flu wave returned particularly aggressively, creating a “twindemic” in which dangerous dual infections from COVID-19 and influenza are also possible..... https://www.wsws.org/en/articles/2022/12/03/mtrj-d03.html P.S. After all the many months of them posting misinformation/disinformation videos of vaccinated professional soccer players collapsing to the ground... FIFA World Cup has not had a single unexplained collapse nor has any player died while playing in a game while the ENTIRE world is watching. Have you noticed they've slithered back into the gutter in hiding with their misinformation/disinformation soccer videos about vaccinated players especially their comment that 1 of 250 vaccinated soccer players have dropped dead from their vaccines. Argentina 3 : Croatia 0 wrbtrader
You two are the pillars of the mutual admiration 69 club, lol. Like me like you like me like you... yawn
Covishield immune response vs Covid variants higher than Covaxin: Study Covishield elicited immune responses of higher magnitude and breadth than Covaxin in both seronegative individuals and seropositive individuals https://www.eastmojo.com/national/2...-vs-covid-variants-higher-than-covaxin-study/
Progress is still being made on a universal coronavirus vaccine. As well as on nasal forms of the vaccine. Two years after Covid vaccines rolled out, researchers are calling for newer, better options Despite the success of mRNA vaccines, researchers think a new generation of Covid vaccines could provide broader, longer-term protection in the future. https://www.nbcnews.com/health/health-news/two-years-covid-vaccines-rcna57902 Two years after the first Covid shots went into arms, a growing chorus of researchers is calling for a new generation of vaccines that provide broader and more long-term protection against the disease. The U.S. is currently recording around 430 Covid deaths per day, on average, according to NBC News’ tally. That includes many people who received at least two Covid shots: Six in 10 adults who died of Covid in August were vaccinated or boosted, according to a report by KFF, a nonprofit health think tank. And for the most part, vaccinated people don’t avoid infections or reinfections anymore. “Coming up with a vaccine that’s going to last longer and cover a wider range of the Covid family of viruses is a life and death problem,” said Dr. Tom Frieden, who directed the Centers for Disease Control and Prevention until 2017 and is now president of the public health organization Resolve to Save Lives. Many people thought the solution to that problem had arrived two years ago, on December 14, 2020, when Sandra Lindsay became the first person in the U.S. to get a Covid vaccine outside of a clinical trial. “My whole life just changed tremendously in that one moment in time,” said Lindsay, who is now the vice president of public health advocacy at Northwell Health. “What was going through my mind is, ‘I cannot wait for this needle to pierce my arm,’” she said. Millions of people shared her impatience, for good reason: Adults who are up to date on their shots are 15 times less likely to die from Covid than those who are unvaccinated. Covid vaccines prevented more than 3.2 million deaths and 18.5 million hospitalizations in the U.S. from December 2020 through November 2022, according to an analysis published Tuesday by the Commonwealth Fund and Yale School of Public Health. But at first, the shots were perceived to be even more powerful than that — a shield against mild symptoms and a ticket back to pre-pandemic life. The reality proved more complicated and, in certain ways, disappointing. Many experts maintain that we can — and must — do better. In particular, researchers think sprays or drops given through the nose or mouth could do a better job of stopping transmission. They also hope that vaccines that target multiple parts of the virus or several variants at once could reduce the need for continuous boosters. “It’s sometimes easy to forget what a tremendous achievement it was to get a brand new vaccine against a brand new class of viruses. … It was pragmatic, and it was tremendously successful. But it’s certainly not the panacea,” said Matthew Miller, scientific director of the Michael G. DeGroote Institute for Infectious Disease Research at McMaster University. “We can certainly improve on what we know now.” The promises and shortcomings of mRNA Vaccine researchers generally agree that mRNA technology was suited to the needs of this pandemic, since it allowed scientists to develop a vaccine quickly at a time when each day meant more lives lost. Scientists then updated the shots relatively easily to target new variants. “If it wasn’t mRNA, it wouldn’t have gotten done so fast,” said Dr. Barney Graham, former deputy director of the National Institutes of Health’s Vaccine Research Center, now a senior adviser for global health equity at Morehouse School of Medicine. To date, he added, the Covid vaccine is “one of our simplest, safest vaccines that we’ve ever made.” When Lindsay got her vaccine in 2020, she was dealing with severely ill Covid patients every day as director of nursing critical care at Long Island Jewish Medical Center. “It felt like you were just walking into a burning building, but it’s your job,” she said. “It’s what I love doing: taking care of people. So I was going in there no matter what, and just praying every day that I don’t fall ill.” Despite the odds, Lindsay still hasn’t gotten Covid, as far as she knows. But the majority of Americans have, according to CDC estimates — a situation most of the public did not anticipate when clinical trial results showed 95% efficacy against symptomatic disease. “It may be that the vaccines were their own worst enemies in some ways, because they were so good initially that people had an expectation that went beyond reason,” Graham said. Experts agree now, though, that protection from Covid shots fades too fast. Plus, a lack of access to vaccines in many countries allowed the virus to spread rampantly and mutate over time, which has undermined vaccines and treatments. “If we had immunized the whole world in six months, we may not be having all the problems with the variants because we would have constrained [the] virus’ spread earlier,” Graham said. The future of Covid vaccines: No needles When Lindsay volunteered to get her vaccine on day one, she wasn’t aware that she was the country’s very first recipient — despite the cameras. Now, she said, she still gets recognized. “I was in TJ Maxx the other day and this man who I didn’t expect was basically bowing down at my feet, [saying] that through my one action, I saved his life, his family’s lives, and so many more,” Lindsay said. “Those are the stories that just solidify for me that what I did on that day made a big difference.” But others see Lindsay as the face of a promise that fell short. “You get this on social media, when you post anything: ‘Well, how do you feel now that this thing was all a lie? People are not supposed to get Covid and you got the shots and it’s a big letdown,’” she said. Researchers still hope that in the future, nasal spray vaccines could inspire more confidence by offering more protection against illness, reducing side effects and removing needles from the equation. Because Covid seems to infect most people through the nasal passages first, administering a vaccine in the nose could vanquish the virus before it has a chance to spread, the thinking goes. “It’s sort of akin to having guards placed outside the door in the mucus layer, versus waiting for the invaders to come in,” said Dr. Akiko Iwasaki, an immunobiology professor at Yale University who is developing an intranasal Covid vaccine. Globally, 117 intranasal Covid vaccines are in development or have been rolled out, according to an analysis provided to NBC News by Airfinity, a health analytics company. Five have been approved in at least one country — two in China and one each in India, Iran and Russia — and 20 more have entered clinical trials. The majority rely on traditional vaccine platforms, not mRNA. “There’s probably a number of advantages to the intranasal route that will be realized once that route is fully exploited. People can administer it themselves. You can use it in a developing world setting. You can use lower doses,” said Dr. David Curiel, a professor of radiation oncology at Washington University School of Medicine in St. Louis. “There may even be a safety gain, and you get sterilizing immunity and possibly block transmission.” Curiel developed the technology for the nasal vaccine approved in India. But the vaccine hasn’t entered trials in the U.S., and trial results from India haven’t been published in a peer-reviewed journal. Other researchers are betting on inhaled vaccines, which come in the form of aerosolized mists administered through a nebulizer into the lungs, where the virus tends to wreak the most havoc. In September, China approved an inhaled version of a previously authorized Covid shot, called Convidecia. A small trial showed that the inhaled booster dose produced a stronger antibody response than a booster of the intramuscular shot. Miller and his McMaster colleagues are testing two inhaled vaccines in phase 1 human trials. The more effective candidate will likely advance to phase 2, he said. Those vaccines might offer an additional advantage, according to Miller: They target three parts of the coronavirus, whereas the current shots target just the spike protein, which mutates faster than the virus’ other components. Still, some researchers worry that protection from nasal or inhaled vaccines could also wane quickly. “If we can give a vaccine at the site where infection typically occurs, we would always love to do it that way. The challenge, of course, is that sometimes it doesn’t generate the same type of bloodstream immunity that we really want,” said Dr. Buddy Creech, director of the Vanderbilt Vaccine Research Program. Creech said future versions of mRNA shots could potentially be tweaked to target three or more coronavirus strains. (The new bivalent boosters target two.) “It will not be surprising if at some point we need something like a trivalent vaccine or some other permutation of what we have now,” he said. “It could very well mirror what we do with influenza.” Then there’s the idea of targeting several different coronaviruses at once. The National Institute of Allergy and Infectious Diseases has allocated more than $62 million for research and development of pan-coronavirus vaccines. In July, researchers at the California Institute of Technology showed that their candidate protected mice and monkeys from the viruses that cause both Covid and SARS. In October, researchers at Duke University School of Medicine similarly showed that their pan-coronavirus vaccine protected animals from multiple SARS-related viruses. But unlike in 2020, the federal government’s motivation to fund Covid-related innovations is drying up. Whatever Covid vaccine comes next is likely three to five years off, Miller estimated — or perhaps longer, according to other experts. “The mRNA technology is remarkably successful — these vaccines work better than we had the right to expect,” Frieden said. “But the virus is adapting. And as the virus adapts, we need to adapt.”
A Vaccine Against COVID-19 Found to Protect Against Infection and Brain Damage Caused by the Virus https://www.nbcnews.com/politics/ec...student-loan-safety-net-forgiveness-rcna65060
Not surprising anyone, J&J is scaling back the production of its Covid vaccine. Their vaccine never caught on seeing how it is less effective than the mRNA vaccines and it is the only vaccine in the U.S. which has proven medically proven deaths associated with it. There have been close to 20 medically proven deaths related to blood clots associated with the J&J vaccine. This is not surprising since its formulation is similar to Astra-Zeneca which has similar blood clot issues. Johnson & Johnson is scaling back COVID-19 vaccine production – WSJ https://seekingalpha.com/news/39245...pany-scaling-back-covid-19-vaccine-production Amid falling demand, Johnson & Johnson (NYSE:JNJ) has significantly cut back the production of its COVID-19 vaccine and terminated manufacturing agreements with companies such as Catalent (NYSE:CTLT) and Sanofi (NASDAQ:SNY) (OTCPK:SNYNF) in recent months, The Wall Street Journal reported Friday. J&J’s (JNJ) production agreement for the shot with Merck (NYSE:MRK) also hangs in the balance. The deal signed with government involvement has yet to yield the expected results, and the companies are currently in talks for arbitration. A Merck (MRK) spokesperson said the company looks forward to presenting its stand to an arbitration panel. Meanwhile, a Sanofi (SNY) spokesperson said that J&J (JNJ) ended the COVID-19 vaccine production deal with the company due to weak demand. In November, contract manufacturer Catalent (CTLT) disclosed it agreed to the early termination of COVID vaccine agreements with J&J (JNJ) for the fill-and-finish part of the production process. The company received $54M from J&J (JNJ) to settle the contracts in October. The report comes as J&J (JNJ) is scheduled to report its Q4 2022 results later this month. With its Q1 2022 results, the company suspended its sales guidance for the vaccine citing a global supply glut and uncertain demand. While J&J (JNJ) was the third company in the U.S. to win FDA nod for a COVID-19 vaccine, rivals Pfizer (PFE)/ BioNTech (BNTX) and Moderna (MRNA) have dominated the U.S. immunization drive. J&J’s (JNJ) vaccine was linked to rare blood clot formation, which prompted the Centers for Disease Control and Prevention (CDC) to pause its use in 2021. However, weeks later, the regulators reintroduced the vaccine, updating the patient fact sheets to reflect the rare side effect.
The progress towards a universal mRNA Flu vaccine appears to be further along than a universal Coronavirus vaccine. New mRNA universal flu vaccine against all known subtypes takes promising first steps https://bigthink.com/health/mrna-universal-flu-vaccine/
As per its normal data reporting and monitoring process, the CDC has found a possible concern with increased strokes among the over age 65 population with the bivalent booster recently. As noted -- it is unlikely to represent a true risk. CDC identifies possible safety issue with Pfizer’s updated Covid-19 vaccine but says people should still get boosted https://www.cnn.com/2023/01/13/health/pfizer-bivalent-booster-safety-cdc/index.html The US Centers for Disease Control and Prevention said Friday that there is a possible safety issue with the bivalent Covid-19 vaccine made by Pfizer and BioNTech but that it is unlikely to represent a true risk. The agency said it continues to recommend that people stay up-to-date with Covid-19 vaccines. The CDC said one of its vaccine safety monitoring systems – a “near real-time surveillance system” called the Vaccine Safety Datalink – detected a possible increase in a certain kind of stroke in people 65 and older who recently got one of Pfizer’s updated booster shots. A rapid response analysis of that signal revealed that seniors who got an bivalent booster might be more likely to have ischemic strokes within the first three weeks after their shots, compared with weeks four through six. Ischemic strokes, the most common form, are blockages of blood to the brain. They’re usually caused by clots. The Vaccine Safety Datalink, or VSD, is a network of large health systems across the nation that provides data about the safety and efficacy of vaccines through patients’ electronic health records. The CDC said it had identified possible confounding factors in the data coming from the VSD that may be biasing the data and need further investigation. Of about 550,000 seniors who got Pfizer bivalent boosters and were tracked by the VSD, 130 had strokes in the three weeks after the shot, according to a CDC official who spoke to CNN on condition of anonymity because they weren’t authorized to share the data. None of the 130 people died. The number of strokes detected is relatively small, said Dr. William Schaffner, an infectious disease expert at Vanderbilt University and a member of the CDC Advisory Committee on Immunization Practices’ Covid-19 Vaccine Work Group. “These strokes are not a confirmed adverse event at the moment,” he said. “It’s like a radar system. You’re getting a blip on the radar, and you have to do further investigation to discover whether that airplane is friend or foe.” The same safety signal has not been detected with the bivalent Moderna booster, the CDC said in its notice. The agency noted that it has looked for and failed to find the same increase in strokes in other large collections of medical records, including those maintained by Medicare, the US Department of Veterans Affairs, as well as its Vaccine Adverse Event Reporting System, known as VAERS. Neither Pfizer nor other countries that are using the vaccine have seen any increase in this kind of stroke, the agency said, and the signal was not detected in any other databases. The CDC says that it does not recommend any change to vaccination practices at this time and that the risks of Covid-19 for older adults continue to outweigh any possible safety issues with the vaccine. “Although the totality of the data currently suggests that it is very unlikely that the signal in VSD represents a true clinical risk, we believe it is important to share this information with the public, as we have in the past, when one of our safety monitoring systems detects a signal,” the notice says. “CDC and FDA will continue to evaluate additional data from these and other vaccine safety systems. These data and additional analyses will be discussed at the upcoming January 26 meeting of the FDA’s Vaccines and Related Biological Products Advisory Committee.” Pfizer said in a statement Friday, “Neither Pfizer and BioNTech nor the CDC or the U.S. Food and Drug Administration (FDA) have observed similar findings across numerous other monitoring systems in the U.S. and globally and there is no evidence to conclude that ischemic stroke is associated with the use of the companies’ COVID-19 vaccines. “Compared to published incidence rates of ischemic stroke in this older population, the companies to date have observed a lower number of reported ischemic strokes following the vaccination with the Omicron BA.4/BA.5-adapted bivalent vaccine.” The bivalent boosters from Pfizer/BioNTech and Moderna protect against the original strain of the coronavirus as well as the Omicron BA.4 and BA.5 subvariants. Only about 50 million Americans ages 5 and up have gotten them since they were authorized last fall, according to CDC data. Schaffner said he was part of a briefing Thursday with members of the Covid-19 Vaccine Work Group. He couldn’t share specific details about the briefing but said the safety signal was discussed. His biggest takeaway was that the safety surveillance system is working. It’s very likely that this is a false signal, he said, but it’s being investigated, which is important. “You want a surveillance system that occasionally sends up false signals. If you don’t get any signals, you’re worried that you’re missing stuff.” Schaffner said he would absolutely tell people to get their Covid-19 booster if they haven’t done so yet – even those 65 and older. “Undoubtedly, the risk of a whole series of adverse events, including hospitalization, is much, much greater with Covid-19 than it is from the vaccine,” he said. He also said the signal – if real – may be more a factor of numbers than an indication that one manufacturer’s vaccine is riskier than the other. Nearly two-thirds of the people in the US who’ve gotten an updated booster – 32 million – have gotten Pfizer, compared with about 18 million Moderna shots.